A Call to Action
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.
Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.
Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]
Early remdesivir to prevent progression to severe Covid-19 in outpatients.
Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.
Neutralization escape by the SARS-CoV-2 Omicron variants BA.2.12.1 and BA.4/BA.5.
Hachmann NP, Miller J, Collier A-rY, et al. medRxiv. 2022. [Epub ahead of print]
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.
At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.
Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.
Levin M, Ustianowski A, De Wit S, et al. N Engl J Med. 2022. [Epub ahead of print]
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Montgomery H, Hobbs FDR, Padilla F, et al. Lancet Respir Med. 2022;10(10):985-996.
Data and clinical considerations for additional doses in immunocompromised people.
Oliver S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; July 22, 2021.
A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic model.
Razonable RR, Aloia NCE, Anderson RJ, et al. Mayo Clin Proc. 2021;96(5):1250-1261.
Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.
Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Clinician Resources
Federal response to COVID-19: monoclonal antibody clinical implementation guide.
Department of Health and Human Services (DHHS).
Fact Sheet for Healthcare Providers: Emergency Use Authorization for bebtelovimab.
US Food and Drug Administration (FDA).
Fact Sheet for Healthcare Providers: Emergency Use Authorization of Evusheld™ (tixagevimab/cilgavimab).
FDA.
Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir).
FDA.
Fact sheet for healthcare providers: emergency use authorization for Paxlovid™.
FDA.
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
OpenData Portal.
NIH.
Patient Resources
Talking with patients about monoclonal antibodies for COVID-19: tips and frequently asked questions.
DHHS.
Monoclonal Antibodies for COVID-19.
Lloyd EC, Gandhi TN, Petty LA. JAMA. 2021;325(10):1015.
A Call to Action
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
| Faculty: | Eric Daar, MD; Lucy Horton, MD; Raymund Razonable, MD; Lewis Teperman, MD; Phyllis Tien, MD; Charles Vega, MD |
| Release: | 10/31/2022 |
| Expiration: | 10/31/2023 |
